Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Conivaptan hydrochloride (Vaprisol) 是一种口服有效的加压素 V2 和 V1A 受体拮抗剂,用于治疗高血容量性低钠血症和正常血容量。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 141 | 现货 | ||
5 mg | ¥ 311 | 现货 | ||
10 mg | ¥ 497 | 现货 | ||
25 mg | ¥ 997 | 现货 | ||
50 mg | ¥ 1,970 | 现货 | ||
100 mg | ¥ 3,470 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 551 | 现货 |
产品描述 | Conivaptan hydrochloride (Vaprisol) is an orally active vasopressin V2 and V1A receptor antagonist, used in the therapy of hypervolemic hyponatremia and euvolemic. |
靶点活性 | V1a (rat liver):0.48nM(Ki), V2 (rat kidney):3.04 nM(Ki) |
体内活性 | Conivaptan (0.03, 0.1 and 0.3 mg/kg i.v.) increases urine volume and reduces urine osmolality in both myocardial infarction and sham-operated rats in dose-dependent manner. Conivaptan (0.3 mg/kg i.v.) significantly reduces right ventricular systolic pressure, left ventricular end-diastolic pressure, lung/body weight and right atrial pressure in myocardial infarction rats. Conivaptan (0.3 mg/kg i.v.) significantly increases dP/dt(max)/left ventricular pressure in myocardial infarction rats. [1] Conivaptan produces an acute increase in urine volume (UV), a reduction in osmolality (UOsm) and, at the end of the investigation, cirrhotic rats receiving the V(1a)/V(2)-AVP receptor antagonist does not show hyponatremia or hypoosmolality. Conivaptan also normalizes U(Na)V without affecting creatinine clearance and arterial pressure. [2] Conivaptan (0.01 to 0.1 mg/kg i.v.) exerts a dose-dependent diuretic effect in dogs without an increase in the urinary excretion of electrolytes, inhibits the pressor effect of exogenous vasopressin in a dose-dependent manner (0.003 to 0.1 mg/kg i.v.) and, at the highest dose (0.1 mg/kg i.v.), almost completely blocks vasoconstriction caused by exogenous vasopressin. Conivaptan (0.1 mg/kg i.v.) improves cardiac function, as evidenced by significant increases in left ventricular dP/dtmax, cardiac output and stroke volume, and reduces preload and afterload, as evidenced by significant decreases in left ventricular end-diastolic pressure and total peripheral vascular resistance in dogs with congestive heart failure. [3] |
别名 | Vaprisol, 盐酸考尼伐坦, Conivaptan HCl, YM 087 |
分子量 | 535.04 |
分子式 | C32H26N4O2·HCl |
CAS No. | 168626-94-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 7 mg/mL (13.08 mM)
DMSO: 99 mg/mL (185 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 1.869 mL | 9.3451 mL | 18.6902 mL | 46.7255 mL |
5 mM | 0.3738 mL | 1.869 mL | 3.738 mL | 9.3451 mL | |
10 mM | 0.1869 mL | 0.9345 mL | 1.869 mL | 4.6725 mL | |
DMSO | 20 mM | 0.0935 mL | 0.4673 mL | 0.9345 mL | 2.3363 mL |
50 mM | 0.0374 mL | 0.1869 mL | 0.3738 mL | 0.9345 mL | |
100 mM | 0.0187 mL | 0.0935 mL | 0.1869 mL | 0.4673 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Conivaptan hydrochloride 168626-94-6 GPCR/G Protein Vasopressin Receptor inhibit Vaprisol YM087 盐酸考尼伐坦 Conivaptan Conivaptan HCl Conivaptan Hydrochloride YM-087 Inhibitor YM 087 inhibitor